Novel insulin peptides

Details Novel insulin peptides Novel insulin peptides

1987-07-20

1990-08-07

Lee, Lester L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530303, A61K 3726, C07K 740

Patent

active

049468286

ABSTRACT:
Insulin derivatives having a charge which is positive compared with the charge of human insulin at neutral pH, can be used to prepare solutions having prolonged insulin action. In the novel insulin derivatives, a basic amino acid has been substituted in the B27-position and/or a neutral amino acid has been inserted in the A4-, A17-, B13- and/or B21-position. Furthermore, the C-terminal carboxyl group of the B-chain may be blocked with an amido or ester residue.

REFERENCES:
patent: 3528960 (1970-09-01), Haas
patent: 3884897 (1975-05-01), Geiger et al.
patent: 4608364 (1986-08-01), Gran
Markussen et al., Protein Engineering, vol. 1, No. 3, pp. 205-213; 215-233 (1987).
Glimeher et al., The Journal of Immunology, vol. 131, No. 6, pp. 2868-2874 (1983).
Knud Hallas-Moller: Chemical and Biological Insulin Studies, Copenhagen, 1945, vol. 1, pp. 180-184.
Geiger & Enzmann: Clinical Application of Insulin Derivatives, Amsterdam-Oxford, 1979, pp. 306-310.
D. A. Scott and A. M. Fisher: The Effect of Zinc Salts on Action of Insulin, J. Pharmacol., 55 (1935), pp. 206-221.

Affiliated with

Also associated with

Rating

Novel insulin peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel insulin peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel insulin peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-960717